Skip Content
 
Page Banner Image

Are HD Clinical Trials Measuring the Right Outcome Measure?

Huntington’s disease (HD) is a progressive neurological condition. Two factors that impede clinical trials in the HD space are the slow progression of the disease that makes it difficult to detect treatment-specific changes over a relatively short period of time and the number of people wanting to know if they are carriers of the mutation.

To read more, click here.


We support those facing huntington disease
 Latest Blog
 Questions

Questions

Have questions? Send us an email at:
E: info@huntingtonsociety.ca

 Connect
 Newsletter

Newsletter

Stay in Touch!
Enter your email address below to receive occasional updates.

Copyright © Huntington Society of Canada. All Rights Reserved. Charitable Registration Number 11896 5516 RR0001